BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pan J, Shi Z, Lin D, Yang N, Meng F, Lin L, Jin Z, Zhou Q, Wu J, Zhang J, Li Y. Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial. Front Med 2020;14:43-50. [PMID: 31907860 DOI: 10.1007/s11684-019-0706-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Gingold-Belfer R, Niv Y, Schmilovitz-Weiss H, Levi Z, Boltin D. Susceptibility-guided versus empirical treatment for Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021. [PMID: 34114673 DOI: 10.1111/jgh.15575] [Reference Citation Analysis]
2 Ouyang Y, Zhang W, He C, Zhu Y, Lu N, Hu Y. Susceptibility-Guided Therapy vs. Bismuth-Containing Quadruple Therapy as the First-Line Treatment for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2022;9:844915. [PMID: 35402425 DOI: 10.3389/fmed.2022.844915] [Reference Citation Analysis]
3 Guo B, Cao NW, Zhou HY, Chu XJ, Li BZ. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis. Microb Pathog 2021;152:104661. [PMID: 33249167 DOI: 10.1016/j.micpath.2020.104661] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 O'connor A, Furuta T, Gisbert JP, O'morain C. Review – Treatment of Helicobacter pylori infection 2020. Helicobacter 2020;25. [DOI: 10.1111/hel.12743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Fauzia KA, Miftahussurur M, Syam AF, Waskito LA, Doohan D, Rezkitha YAA, Matsumoto T, Tuan VP, Akada J, Yonezawa H, Kamiya S, Yamaoka Y. Biofilm Formation and Antibiotic Resistance Phenotype of Helicobacter pylori Clinical Isolates. Toxins (Basel) 2020;12:E473. [PMID: 32722296 DOI: 10.3390/toxins12080473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
6 Kong S, Huang K, Wang J, Wang X, Yang N, Dong Y, Zhuang Y, Dang Y, Zhang G, Ye F. Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study. Gut Pathog 2020;12:39. [PMID: 32874206 DOI: 10.1186/s13099-020-00378-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Kong S, Chen H, Huang K, Jin D, Zhang G, Ye F. Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report. Medicine (Baltimore) 2021;100:e24915. [PMID: 33725850 DOI: 10.1097/MD.0000000000024915] [Reference Citation Analysis]
8 Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? Therap Adv Gastroenterol. 2020;13:1756284820968736. [PMID: 33240392 DOI: 10.1177/1756284820968736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
9 Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother 2021;22:729-41. [PMID: 33131337 DOI: 10.1080/14656566.2020.1845649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
10 Nyssen OP, Espada M, Gisbert JP. Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Front Microbiol 2022;13:913436. [DOI: 10.3389/fmicb.2022.913436] [Reference Citation Analysis]